<article article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Br. J. Cancer</journal-id><journal-title-group><journal-title>British Journal of Cancer</journal-title></journal-title-group><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23928661</article-id><article-id pub-id-type="pmc">3778304</article-id><article-id pub-id-type="pii">bjc2013458</article-id><article-id pub-id-type="doi">10.1038/bjc.2013.458</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Study</subject></subj-group></article-categories><title-group><article-title>Critical weight loss is a major prognostic indicator for disease-specific survival in patients with head and neck cancer receiving radiotherapy</article-title><alt-title alt-title-type="running">Weight loss and survival in head and neck cancer</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Langius</surname><given-names>J A E</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="caf1">*</xref></contrib><contrib contrib-type="author"><name><surname>Bakker</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Rietveld</surname><given-names>D H F</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kruizenga</surname><given-names>H M</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Langendijk</surname><given-names>J A</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Weijs</surname><given-names>P J M</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Leemans</surname><given-names>C R</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><aff id="aff1"><label>1</label><institution>Department of Nutrition and Dietetics, Internal Medicine, VU University Medical Center</institution>, PO Box 7057, 1007 MB Amsterdam, <country>The Netherlands</country></aff><aff id="aff2"><label>2</label><institution>Department of Radiation Oncology, VU University Medical Center</institution>, PO Box 7057, 1007 MB Amsterdam, <country>The Netherlands</country></aff><aff id="aff3"><label>3</label><institution>Department of Radiation Oncology, University Medical Center Groningen, University of Groningen</institution>, PO Box 30.001, 9700 RB Groningen, <country>The Netherlands</country></aff><aff id="aff4"><label>4</label><institution>Department of Otolaryngology/Head and Neck Surgery, VU University Medical Center</institution>, PO Box 7057, 1007 MB <country>Amsterdam</country>, <country>The Netherlands</country></aff></contrib-group><author-notes><corresp id="caf1"><label>*</label>E-mail: <email>j.langius@vumc.nl</email></corresp></author-notes><pub-date pub-type="ppub"><day>03</day><month>09</month><year>2013</year></pub-date><pub-date pub-type="epub"><day>08</day><month>08</month><year>2013</year></pub-date><volume>109</volume><issue>5</issue><fpage>1093</fpage><lpage>1099</lpage><history><date date-type="received"><day>02</day><month>04</month><year>2013</year></date><date date-type="rev-recd"><day>14</day><month>07</month><year>2013</year></date><date date-type="accepted"><day>21</day><month>07</month><year>2013</year></date></history><permissions><copyright-statement>Copyright © 2013 Cancer Research UK</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Cancer Research UK</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0/"><license-p>From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/</license-p></license></permissions><abstract><sec><title><offsets xml_i="4332" xml_f="4343" txt_i="11" txt_f="22">Background:</offsets></title><p><offsets xml_i="4354" xml_f="4610" txt_i="23" txt_f="279">Pre-treatment weight loss (WL) is a prognostic indicator for overall survival (OS) in head and neck cancer (HNC) patients. This study investigates the association between WL before or during radiotherapy and disease-specific survival (DSS) in HNC patients.</offsets></p></sec><sec><title><offsets xml_i="4632" xml_f="4640" txt_i="281" txt_f="289">Methods:</offsets></title><p><offsets xml_i="4651" xml_f="5053" txt_i="290" txt_f="686">In 1340 newly diagnosed HNC patients, weight change was collected before and during (adjuvant) radiotherapy with curative intent. Critical WL during radiotherapy was defined as &gt;5% WL during radiotherapy or &gt;7.5% WL until week 12. Differences in 5-year OS and DSS between WL groups were analysed by Cox's regression with adjustments for important socio-demographic and tumour-related confounders.</offsets></p></sec><sec><title><offsets xml_i="5075" xml_f="5083" txt_i="688" txt_f="696">Results:</offsets></title><p><offsets xml_i="5094" xml_f="5275" txt_i="697" txt_f="872">Before radiotherapy, 70% of patients had no WL, 16% had ⩽5% WL, 9% had &gt;5–10% WL, and 5% had &gt;10% WL. Five-year OS and DSS rates for these groups were 71%, 59%, 47%, and 42% (</offsets><italic><offsets xml_i="5283" xml_f="5284" txt_i="872" txt_f="873">P</offsets></italic><offsets xml_i="5293" xml_f="5347" txt_i="873" txt_f="924">&lt;0.001), and 86%, 86%, 81%, and 71%, respectively (</offsets><italic><offsets xml_i="5355" xml_f="5356" txt_i="924" txt_f="925">P</offsets></italic><offsets xml_i="5365" xml_f="5527" txt_i="925" txt_f="1081">&lt;0.001). After adjustment for potential confounders, &gt;10% WL before radiotherapy remained significantly associated with a worse OS (HR 1.7; 95% CI 1.2–2.5; </offsets><italic><offsets xml_i="5535" xml_f="5537" txt_i="1081" txt_f="1083">P=</offsets></italic><offsets xml_i="5546" xml_f="5586" txt_i="1083" txt_f="1123">0.002) and DSS (HR 2.1; 95% CI 1.2–3.5; </offsets><italic><offsets xml_i="5594" xml_f="5596" txt_i="1123" txt_f="1125">P=</offsets></italic><offsets xml_i="5605" xml_f="5612" txt_i="1125" txt_f="1132">0.007).</offsets></p><p><offsets xml_i="5619" xml_f="5775" txt_i="1133" txt_f="1289">The 5-year OS and DSS rates for patients with critical WL during radiotherapy were 62% and 82%, compared with 70% and 89% for patients without critical WL (</offsets><italic><offsets xml_i="5783" xml_f="5785" txt_i="1289" txt_f="1291">P=</offsets></italic><offsets xml_i="5794" xml_f="5800" txt_i="1291" txt_f="1297">0.01; </offsets><italic><offsets xml_i="5808" xml_f="5810" txt_i="1297" txt_f="1299">P=</offsets></italic><offsets xml_i="5819" xml_f="5953" txt_i="1299" txt_f="1433">0.001). After adjustment, critical WL during radiotherapy remained significantly associated with a worse DSS (HR 1.7; 95% CI 1.2–2.4; </offsets><italic><offsets xml_i="5961" xml_f="5963" txt_i="1433" txt_f="1435">P=</offsets></italic><offsets xml_i="5972" xml_f="5979" txt_i="1435" txt_f="1442">0.004).</offsets></p></sec><sec><title><offsets xml_i="6001" xml_f="6012" txt_i="1444" txt_f="1455">Conclusion:</offsets></title><p><offsets xml_i="6023" xml_f="6224" txt_i="1456" txt_f="1657">Weight loss both before and during radiotherapy are important prognostic indicators for 5-year DSS in HNC patients. Randomised studies into the prognostic effect of nutritional intervention are needed.</offsets></p></sec></abstract><kwd-group><kwd>head and neck cancer</kwd><kwd>weight loss</kwd><kwd>radiotherapy</kwd><kwd>overall survival</kwd><kwd>disease-specific survival</kwd><kwd>malnutrition</kwd></kwd-group></article-meta></front><body><p><offsets xml_i="6462" xml_f="6745" txt_i="1666" txt_f="1949">Patients with head and neck cancer are predominantly at risk for malnutrition due to anorexia, sequelae of the treatment that hamper food intake (e.g., xerostomia or dysphagia) and metabolic alterations as a result of inflammation, which can be induced by the tumour or the therapy (</offsets><xref ref-type="bibr" rid="bib37"><offsets xml_i="6779" xml_f="6806" txt_i="1949" txt_f="1976">Van Cutsem and Arends, 2005</offsets></xref><offsets xml_i="6813" xml_f="6815" txt_i="1976" txt_f="1978">; </offsets><xref ref-type="bibr" rid="bib2"><offsets xml_i="6848" xml_f="6861" txt_i="1978" txt_f="1991">Baracos, 2006</offsets></xref><offsets xml_i="6868" xml_f="6870" txt_i="1991" txt_f="1993">; </offsets><xref ref-type="bibr" rid="bib31"><offsets xml_i="6904" xml_f="6911" txt_i="1993" txt_f="2000">Richey </offsets><italic><offsets xml_i="6919" xml_f="6924" txt_i="2000" txt_f="2005">et al</offsets></italic><offsets xml_i="6933" xml_f="6939" txt_i="2005" txt_f="2011">, 2007</offsets></xref><offsets xml_i="6946" xml_f="6948" txt_i="2011" txt_f="2013">; </offsets><xref ref-type="bibr" rid="bib32"><offsets xml_i="6982" xml_f="6989" txt_i="2013" txt_f="2020">Silver </offsets><italic><offsets xml_i="6997" xml_f="7002" txt_i="2020" txt_f="2025">et al</offsets></italic><offsets xml_i="7011" xml_f="7017" txt_i="2025" txt_f="2031">, 2007</offsets></xref><offsets xml_i="7024" xml_f="7222" txt_i="2031" txt_f="2229">). Malnutrition is a subacute or chronic state in which a combination of varying degrees of undernutrition and inflammatory activity has led to a change in body composition and diminished function (</offsets><xref ref-type="bibr" rid="bib33"><offsets xml_i="7256" xml_f="7264" txt_i="2229" txt_f="2237">Soeters </offsets><italic><offsets xml_i="7272" xml_f="7277" txt_i="2237" txt_f="2242">et al</offsets></italic><offsets xml_i="7286" xml_f="7292" txt_i="2242" txt_f="2248">, 2008</offsets></xref><offsets xml_i="7299" xml_f="7358" txt_i="2248" txt_f="2307">). Weight loss is one of the main symptoms of malnutrition.</offsets></p><p><offsets xml_i="7365" xml_f="7452" txt_i="2308" txt_f="2395">Weight loss is a frequently observed problem among patients with head and neck cancer (</offsets><xref ref-type="bibr" rid="bib14"><offsets xml_i="7486" xml_f="7502" txt_i="2395" txt_f="2411">Jager-Wittenaar </offsets><italic><offsets xml_i="7510" xml_f="7515" txt_i="2411" txt_f="2416">et al</offsets></italic><offsets xml_i="7524" xml_f="7530" txt_i="2416" txt_f="2422">, 2007</offsets></xref><offsets xml_i="7537" xml_f="7539" txt_i="2422" txt_f="2424">; </offsets><xref ref-type="bibr" rid="bib10"><offsets xml_i="7573" xml_f="7581" txt_i="2424" txt_f="2432">Ehrsson </offsets><italic><offsets xml_i="7589" xml_f="7594" txt_i="2432" txt_f="2437">et al</offsets></italic><offsets xml_i="7603" xml_f="7609" txt_i="2437" txt_f="2443">, 2010</offsets></xref><offsets xml_i="7616" xml_f="7758" txt_i="2443" txt_f="2585">). Malnutrition before treatment may be seen in as high as 63% of patients, and its prevalence is associated with the location of the tumour (</offsets><xref ref-type="bibr" rid="bib24"><offsets xml_i="7792" xml_f="7798" txt_i="2585" txt_f="2591">Nayel </offsets><italic><offsets xml_i="7806" xml_f="7811" txt_i="2591" txt_f="2596">et al</offsets></italic><offsets xml_i="7820" xml_f="7826" txt_i="2596" txt_f="2602">, 1992</offsets></xref><offsets xml_i="7833" xml_f="7835" txt_i="2602" txt_f="2604">; </offsets><xref ref-type="bibr" rid="bib1"><offsets xml_i="7868" xml_f="7876" txt_i="2604" txt_f="2612">Argiris </offsets><italic><offsets xml_i="7884" xml_f="7889" txt_i="2612" txt_f="2617">et al</offsets></italic><offsets xml_i="7898" xml_f="7904" txt_i="2617" txt_f="2623">, 2004</offsets></xref><offsets xml_i="7911" xml_f="7913" txt_i="2623" txt_f="2625">; </offsets><xref ref-type="bibr" rid="bib35"><offsets xml_i="7947" xml_f="7953" txt_i="2625" txt_f="2631">Unsal </offsets><italic><offsets xml_i="7961" xml_f="7966" txt_i="2631" txt_f="2636">et al</offsets></italic><offsets xml_i="7975" xml_f="7981" txt_i="2636" txt_f="2642">, 2006</offsets></xref><offsets xml_i="7988" xml_f="7990" txt_i="2642" txt_f="2644">; </offsets><xref ref-type="bibr" rid="bib14"><offsets xml_i="8024" xml_f="8040" txt_i="2644" txt_f="2660">Jager-Wittenaar </offsets><italic><offsets xml_i="8048" xml_f="8053" txt_i="2660" txt_f="2665">et al</offsets></italic><offsets xml_i="8062" xml_f="8068" txt_i="2665" txt_f="2671">, 2007</offsets></xref><offsets xml_i="8075" xml_f="8077" txt_i="2671" txt_f="2673">; </offsets><xref ref-type="bibr" rid="bib4"><offsets xml_i="8110" xml_f="8118" txt_i="2673" txt_f="2681">Capuano </offsets><italic><offsets xml_i="8126" xml_f="8131" txt_i="2681" txt_f="2686">et al</offsets></italic><offsets xml_i="8140" xml_f="8146" txt_i="2686" txt_f="2692">, 2010</offsets></xref><offsets xml_i="8153" xml_f="8155" txt_i="2692" txt_f="2694">, </offsets><xref ref-type="bibr" rid="bib5"><offsets xml_i="8188" xml_f="8192" txt_i="2694" txt_f="2698">2008</offsets></xref><offsets xml_i="8199" xml_f="8201" txt_i="2698" txt_f="2700">; </offsets><xref ref-type="bibr" rid="bib17"><offsets xml_i="8235" xml_f="8243" txt_i="2700" txt_f="2708">Langius </offsets><italic><offsets xml_i="8251" xml_f="8256" txt_i="2708" txt_f="2713">et al</offsets></italic><offsets xml_i="8265" xml_f="8271" txt_i="2713" txt_f="2719">, 2010</offsets></xref><offsets xml_i="8278" xml_f="8563" txt_i="2719" txt_f="3004">). During treatment, many patients develop treatment-related toxicities, of which dysphagia caused by mucositis is one of the most prominent. These acute toxicities result in discomfort and difficulties with eating. During radiotherapy, the prevalence of malnutrition rises to 41–88% (</offsets><xref ref-type="bibr" rid="bib24"><offsets xml_i="8597" xml_f="8603" txt_i="3004" txt_f="3010">Nayel </offsets><italic><offsets xml_i="8611" xml_f="8616" txt_i="3010" txt_f="3015">et al</offsets></italic><offsets xml_i="8625" xml_f="8631" txt_i="3015" txt_f="3021">, 1992</offsets></xref><offsets xml_i="8638" xml_f="8640" txt_i="3021" txt_f="3023">; </offsets><xref ref-type="bibr" rid="bib35"><offsets xml_i="8674" xml_f="8680" txt_i="3023" txt_f="3029">Unsal </offsets><italic><offsets xml_i="8688" xml_f="8693" txt_i="3029" txt_f="3034">et al</offsets></italic><offsets xml_i="8702" xml_f="8708" txt_i="3034" txt_f="3040">, 2006</offsets></xref><offsets xml_i="8715" xml_f="8717" txt_i="3040" txt_f="3042">; </offsets><xref ref-type="bibr" rid="bib17"><offsets xml_i="8751" xml_f="8759" txt_i="3042" txt_f="3050">Langius </offsets><italic><offsets xml_i="8767" xml_f="8772" txt_i="3050" txt_f="3055">et al</offsets></italic><offsets xml_i="8781" xml_f="8787" txt_i="3055" txt_f="3061">, 2010</offsets></xref><offsets xml_i="8794" xml_f="8908" txt_i="3061" txt_f="3175">). Sequelae of radiation therapy and weight loss may continue for several weeks after completion of radiotherapy (</offsets><xref ref-type="bibr" rid="bib17"><offsets xml_i="8942" xml_f="8950" txt_i="3175" txt_f="3183">Langius </offsets><italic><offsets xml_i="8958" xml_f="8963" txt_i="3183" txt_f="3188">et al</offsets></italic><offsets xml_i="8972" xml_f="8978" txt_i="3188" txt_f="3194">, 2010</offsets></xref><offsets xml_i="8985" xml_f="8987" txt_i="3194" txt_f="3196">; </offsets><xref ref-type="bibr" rid="bib20"><offsets xml_i="9021" xml_f="9029" txt_i="3196" txt_f="3204">Mehanna </offsets><italic><offsets xml_i="9037" xml_f="9042" txt_i="3204" txt_f="3209">et al</offsets></italic><offsets xml_i="9051" xml_f="9057" txt_i="3209" txt_f="3215">, 2010</offsets></xref><offsets xml_i="9064" xml_f="9066" txt_i="3215" txt_f="3217">).</offsets></p><p><offsets xml_i="9073" xml_f="9180" txt_i="3218" txt_f="3325">It has been demonstrated that weight loss before treatment is a prognostic indicator for overall survival (</offsets><xref ref-type="bibr" rid="bib3"><offsets xml_i="9213" xml_f="9226" txt_i="3325" txt_f="3338">Brookes, 1985</offsets></xref><offsets xml_i="9233" xml_f="9235" txt_i="3338" txt_f="3340">; </offsets><xref ref-type="bibr" rid="bib29"><offsets xml_i="9269" xml_f="9278" txt_i="3340" txt_f="3349">Pugliano </offsets><italic><offsets xml_i="9286" xml_f="9291" txt_i="3349" txt_f="3354">et al</offsets></italic><offsets xml_i="9300" xml_f="9306" txt_i="3354" txt_f="3360">, 1999</offsets></xref><offsets xml_i="9313" xml_f="9315" txt_i="3360" txt_f="3362">; </offsets><xref ref-type="bibr" rid="bib36"><offsets xml_i="9349" xml_f="9382" txt_i="3362" txt_f="3395">Van Bokhorst-de van der Schueren </offsets><italic><offsets xml_i="9390" xml_f="9395" txt_i="3395" txt_f="3400">et al</offsets></italic><offsets xml_i="9404" xml_f="9410" txt_i="3400" txt_f="3406">, 1999</offsets></xref><offsets xml_i="9417" xml_f="9419" txt_i="3406" txt_f="3408">; </offsets><xref ref-type="bibr" rid="bib25"><offsets xml_i="9453" xml_f="9474" txt_i="3408" txt_f="3429">Nguyen and Yueh, 2002</offsets></xref><offsets xml_i="9481" xml_f="9483" txt_i="3429" txt_f="3431">; </offsets><xref ref-type="bibr" rid="bib8"><offsets xml_i="9516" xml_f="9532" txt_i="3431" txt_f="3447">De Cassia Braga </offsets><italic><offsets xml_i="9540" xml_f="9545" txt_i="3447" txt_f="3452">et al</offsets></italic><offsets xml_i="9554" xml_f="9560" txt_i="3452" txt_f="3458">, 2003</offsets></xref><offsets xml_i="9567" xml_f="9569" txt_i="3458" txt_f="3460">; </offsets><xref ref-type="bibr" rid="bib1"><offsets xml_i="9602" xml_f="9610" txt_i="3460" txt_f="3468">Argiris </offsets><italic><offsets xml_i="9618" xml_f="9623" txt_i="3468" txt_f="3473">et al</offsets></italic><offsets xml_i="9632" xml_f="9638" txt_i="3473" txt_f="3479">, 2004</offsets></xref><offsets xml_i="9645" xml_f="9647" txt_i="3479" txt_f="3481">; </offsets><xref ref-type="bibr" rid="bib38"><offsets xml_i="9681" xml_f="9695" txt_i="3481" txt_f="3495">Van Den Broek </offsets><italic><offsets xml_i="9703" xml_f="9708" txt_i="3495" txt_f="3500">et al</offsets></italic><offsets xml_i="9717" xml_f="9723" txt_i="3500" txt_f="3506">, 2004</offsets></xref><offsets xml_i="9730" xml_f="9732" txt_i="3506" txt_f="3508">; </offsets><xref ref-type="bibr" rid="bib28"><offsets xml_i="9766" xml_f="9775" txt_i="3508" txt_f="3517">Pedruzzi </offsets><italic><offsets xml_i="9783" xml_f="9788" txt_i="3517" txt_f="3522">et al</offsets></italic><offsets xml_i="9797" xml_f="9803" txt_i="3522" txt_f="3528">, 2008</offsets></xref><offsets xml_i="9810" xml_f="9812" txt_i="3528" txt_f="3530">).</offsets></p><p><offsets xml_i="9819" xml_f="9999" txt_i="3531" txt_f="3711">As the association between weight loss before or during radiotherapy and disease-specific survival in patients with head and neck cancer is unclear, we set out to investigate this.</offsets></p><sec sec-type="materials|methods"><title><offsets xml_i="10044" xml_f="10065" txt_i="3712" txt_f="3733">Materials and methods</offsets></title><sec><title><offsets xml_i="10085" xml_f="10101" txt_i="3734" txt_f="3750">Study population</offsets></title><p><offsets xml_i="10112" xml_f="10229" txt_i="3751" txt_f="3868">A consecutive cohort of head and neck cancer patients treated by radiotherapy between January 2000 and January 2009 (</offsets><italic><offsets xml_i="10237" xml_f="10238" txt_i="3868" txt_f="3869">n</offsets></italic><offsets xml_i="10247" xml_f="10570" txt_i="3869" txt_f="4192">=1799) was investigated for inclusion in this study. Main inclusion criterion was curative radiotherapy, either as sole treatment (with or without chemotherapy) or postoperatively. Patients younger than 18 years, patients with a tumour of the ear, skin, or oesophagus, and those with previous cancer history were excluded (</offsets><xref ref-type="fig" rid="fig1"><offsets xml_i="10602" xml_f="10610" txt_i="4192" txt_f="4200">Figure 1</offsets></xref><offsets xml_i="10617" xml_f="10780" txt_i="4200" txt_f="4363">). The final study population was composed of 1340 patients. This study was approved by the Medical Ethics Committee of the VU University Medical Center Amsterdam.</offsets></p></sec><sec><title><offsets xml_i="10802" xml_f="10814" txt_i="4365" txt_f="4377">Radiotherapy</offsets></title><p><offsets xml_i="10825" xml_f="11901" txt_i="4378" txt_f="5454">All patients were treated on 6-MV linear accelerators (Varian Medical Systems, Inc., Palo Alto, CA, USA), immobilised in the supine position by the use of individually designed facial masks. From January 2000, conventional three-dimensional conformal radiotherapy was applied until the clinical introduction of parotid gland sparing IMRT in October 2004. In the primary irradiated patients, the tumour and lymph-node metastases were treated with 2 Gy per fraction up to a total dose of 70 Gy. A dose of 46 Gy in daily fractions of 2 Gy (or an equivalent dose of 35 daily fractions of 1.55 Gy) was given to the elective nodal areas. Patients treated with postoperative radiotherapy received 2-Gy daily fractions at the primary site and nodal metastases to a total dose of 56 or 66 Gy, depending on the surgical margin status and the presence of extranodal spread. Again the elective dose was 46 Gy in 2-Gy daily fractions (or an equivalent dose of 28 fractions of 1.8 Gy or 33 fractions of 1.65 Gy). In the case of concomitant chemoradiation, three cycles of cisplatin 100 mg m</offsets><sup><offsets xml_i="11906" xml_f="11908" txt_i="5454" txt_f="5456">−2</offsets></sup><offsets xml_i="11914" xml_f="11948" txt_i="5456" txt_f="5490"> were given on days 1, 22, and 43.</offsets></p><p><offsets xml_i="11955" xml_f="12301" txt_i="5491" txt_f="5837">From the start of radiotherapy, patients received dietary counselling to achieve individual nutritional requirements. If nutritional requirements could not be reached by regular food products, then energy-enriched oral nutritional supplements and/or enteral tube feeding by nasogastric tube or percutaneous endoscopic gastrostomy were subscribed.</offsets></p></sec><sec><title><offsets xml_i="12323" xml_f="12338" txt_i="5839" txt_f="5854">Data collection</offsets></title><p><offsets xml_i="12349" xml_f="13154" txt_i="5855" txt_f="6654">All data were prospectively collected. At baseline, patient and tumour characteristics were recorded. Weight loss before radiotherapy was recalled by the radiotherapist and, based on the equation (current weight−usual weight)/usual weight × 100%, categorised into four groups: no weight loss, ⩽5% weight loss, &gt;5–10% weight loss and &gt;10% weight loss. Body weight was measured at the start of radiotherapy (±7 days) and weekly thereafter until the eighth week, and at 12 weeks after the start of radiotherapy (labelled as ‘during radiotherapy'). Body weight was measured by wearing light indoor clothing and shoes on a digital electronic scale (Seca (Hamburg, Germany), Alpha 770) to the nearest 0.1 kg. Weight was corrected for clothing and shoes by subtracting 2.0 kg for men and 1.3 kg for women (</offsets><xref ref-type="bibr" rid="bib11"><offsets xml_i="13188" xml_f="13210" txt_i="6654" txt_f="6676">Frank and Dunlop, 2000</offsets></xref><offsets xml_i="13217" xml_f="13219" txt_i="6676" txt_f="6678">).</offsets></p></sec><sec><title><offsets xml_i="13241" xml_f="13252" txt_i="6680" txt_f="6691">Definitions</offsets></title><p><offsets xml_i="13263" xml_f="13448" txt_i="6692" txt_f="6871">Critical weight loss was defined as body weight loss of &gt;5% from the start of radiotherapy until week 8 or &gt;7.5% until week 12 according to the international consensus statement (</offsets><xref ref-type="bibr" rid="bib40"><offsets xml_i="13482" xml_f="13488" txt_i="6871" txt_f="6877">White </offsets><italic><offsets xml_i="13496" xml_f="13501" txt_i="6877" txt_f="6882">et al</offsets></italic><offsets xml_i="13510" xml_f="13516" txt_i="6882" txt_f="6888">, 2012</offsets></xref><offsets xml_i="13523" xml_f="13648" txt_i="6888" txt_f="7013">). Because we earlier observed that acute radiotherapy induced toxicity and weight loss arise after 2 weeks of radiotherapy (</offsets><xref ref-type="bibr" rid="bib17"><offsets xml_i="13682" xml_f="13690" txt_i="7013" txt_f="7021">Langius </offsets><italic><offsets xml_i="13698" xml_f="13703" txt_i="7021" txt_f="7026">et al</offsets></italic><offsets xml_i="13712" xml_f="13718" txt_i="7026" txt_f="7032">, 2010</offsets></xref><offsets xml_i="13725" xml_f="13837" txt_i="7032" txt_f="7144">), the time span for critical weight loss during radiotherapy was expected to be the last month of radiotherapy.</offsets></p><p><offsets xml_i="13844" xml_f="14508" txt_i="7145" txt_f="7809">Overall survival was defined as the time elapsed between the start of radiotherapy and the date of death of any cause, or if the patient was still alive, and 5 years after the start of radiotherapy. Disease-specific survival was defined as the time elapsed between the start of radiotherapy and the date of death due to cancer, or if the patient was still alive, and 5 years after the start of radiotherapy. Patients who were lost to follow-up within 5 years were censored at their last date of follow-up. In the analysis of disease-specific survival, deaths due to causes other than head and neck cancer were treated as censored observations at the time of death.</offsets></p></sec><sec><title><offsets xml_i="14530" xml_f="14550" txt_i="7811" txt_f="7831">Statistical analysis</offsets></title><p><offsets xml_i="14561" xml_f="14668" txt_i="7832" txt_f="7939">To test differences in patient, tumour, and treatment characteristics between survivors and non-survivors, </offsets><italic><offsets xml_i="14676" xml_f="14677" txt_i="7939" txt_f="7940">χ</offsets></italic><sup><offsets xml_i="14691" xml_f="14692" txt_i="7940" txt_f="7941">2</offsets></sup><offsets xml_i="14698" xml_f="14761" txt_i="7941" txt_f="8004"> tests were used regarding gender, tumour location, TNM stage (</offsets><xref ref-type="bibr" rid="bib9"><offsets xml_i="14794" xml_f="14799" txt_i="8004" txt_f="8009">Edge </offsets><italic><offsets xml_i="14807" xml_f="14812" txt_i="8009" txt_f="8014">et al</offsets></italic><offsets xml_i="14821" xml_f="14827" txt_i="8014" txt_f="8020">, 2010</offsets></xref><offsets xml_i="14834" xml_f="14974" txt_i="8020" txt_f="8160">), baseline WHO performance score, weight loss before radiotherapy, treatment modality, and radiotherapy on the neck nodes, and independent </offsets><italic><offsets xml_i="14982" xml_f="14983" txt_i="8160" txt_f="8161">t</offsets></italic><offsets xml_i="14992" xml_f="15021" txt_i="8161" txt_f="8190"> test was used regarding age.</offsets></p><p><offsets xml_i="15028" xml_f="15389" txt_i="8191" txt_f="8552">Survival curves were generated using the method of Kaplan–Meier. The log-rank test was used to examine the difference in overall and disease-specific survival between weight loss groups. Cox's proportional hazard models were used to build multivariate (i.e., adjusted) models. Relevant factors influencing both weight loss and the survival period were selected </offsets><italic><offsets xml_i="15397" xml_f="15405" txt_i="8552" txt_f="8560">a priori</offsets></italic><offsets xml_i="15414" xml_f="16344" txt_i="8560" txt_f="9484">, based on the literature. Potential confounder variables for the association between weight loss before radiotherapy and overall and disease-specific survival were age, gender, tumour location (oral cavity, oropharynx, nasopharynx, hypopharynx, larynx, nasal cavity and paranasal sinuses, major salivary glands, and unknown primary), TNM stage (I, II, III, and IV), prior head and neck surgery, and baseline WHO performance score (0, 1, and 2/3). For the association between weight loss during radiotherapy and overall and disease-specific survival, we additionally adjusted for weight loss before radiotherapy (no weight loss, ⩽5% weight loss, &gt;5–10% weight loss, and &gt;10% weight loss), treatment modality (RT alone, RT+surgery, and RT+chemotherapy±surgery), and radiotherapy on the neck nodes (none, unilateral, and bilateral). We attempted to adjust for comorbidity by the Adult Comorbidity Evaluation-27 (ACE-27) test (</offsets><xref ref-type="bibr" rid="bib27"><offsets xml_i="16378" xml_f="16400" txt_i="9484" txt_f="9506">Paleri and Wight, 2002</offsets></xref><offsets xml_i="16407" xml_f="16649" txt_i="9506" txt_f="9748">), but the scores were available only in patients receiving chemoradiotherapy. Therefore, a subgroup analyses was performed to analyse the effect of comorbidity on the association between weight loss and overall and disease-specific survival.</offsets></p><p><offsets xml_i="16656" xml_f="16966" txt_i="9749" txt_f="10059">Interaction between weight loss and gender or age with respect to overall and disease-specific survival was investigated, but both were no effect modifiers. Proportional hazard assumptions for each model was investigated and confirmed by testing the constancy over time of the log-hazard ratio for each model. </offsets><italic><offsets xml_i="16974" xml_f="16975" txt_i="10059" txt_f="10060">P</offsets></italic><offsets xml_i="16984" xml_f="17156" txt_i="10060" txt_f="10229">-values of &lt;0.05 were considered as statistically significant. Analyses were performed using the SPSS software (version 20.0.0; 2011 IBM Corporation, New York, NY, USA).</offsets></p></sec></sec><sec sec-type="results"><title><offsets xml_i="17203" xml_f="17210" txt_i="10232" txt_f="10239">Results</offsets></title><p><offsets xml_i="17221" xml_f="17580" txt_i="10240" txt_f="10599">The majority of patients (70%) were male. The mean age was 61.4±12.0 years, and ranged from 19 to 96 years. Tumours were mainly located at the larynx and oropharynx. Eighteen percent of patients had stage I tumours, 21% stage II, 18% stage III, whereas 43% had stage IV tumours. Slightly more than half of the patients received a combined modality treatment (</offsets><xref rid="tbl1" ref-type="table"><offsets xml_i="17614" xml_f="17621" txt_i="10599" txt_f="10606">Table 1</offsets></xref><offsets xml_i="17628" xml_f="17630" txt_i="10606" txt_f="10608">).</offsets></p><p><offsets xml_i="17637" xml_f="18034" txt_i="10609" txt_f="11006">Four-hundred and seventy-one patients (35%) died within 5 years. No significant difference was found between the survivors and the non-survivors regarding gender. There were significant differences between the survivors and the non-survivors regarding age, tumour location, TNM stage, weight loss before radiotherapy, WHO performance score, treatment modality, and radiotherapy on the neck nodes (</offsets><xref rid="tbl1" ref-type="table"><offsets xml_i="18068" xml_f="18075" txt_i="11006" txt_f="11013">Table 1</offsets></xref><offsets xml_i="18082" xml_f="18084" txt_i="11013" txt_f="11015">).</offsets></p><sec><title><offsets xml_i="18100" xml_f="18131" txt_i="11016" txt_f="11047">Weight loss before radiotherapy</offsets></title><p><offsets xml_i="18142" xml_f="18286" txt_i="11048" txt_f="11186">Before radiotherapy, 70% of patients had no weight loss, 16% had ⩽5% weight loss, 9% had &gt;5–10% weight loss, and 5% had &gt;10% weight loss (</offsets><xref rid="tbl1" ref-type="table"><offsets xml_i="18320" xml_f="18327" txt_i="11186" txt_f="11193">Table 1</offsets></xref><offsets xml_i="18334" xml_f="18440" txt_i="11193" txt_f="11299">). Five-year overall survival rates for these groups were 71%, 59%, 47%, and 42%, respectively (log rank: </offsets><italic><offsets xml_i="18448" xml_f="18449" txt_i="11299" txt_f="11300">P</offsets></italic><offsets xml_i="18458" xml_f="18469" txt_i="11300" txt_f="11308">&lt;0.001; </offsets><xref ref-type="fig" rid="fig2"><offsets xml_i="18501" xml_f="18509" txt_i="11308" txt_f="11316">Figure 2</offsets></xref><offsets xml_i="18516" xml_f="18631" txt_i="11316" txt_f="11431">). Five-year disease-specific survival rates for these groups were 86%, 86%, 81%, and 71%, respectively (log rank: </offsets><italic><offsets xml_i="18639" xml_f="18640" txt_i="11431" txt_f="11432">P</offsets></italic><offsets xml_i="18649" xml_f="18660" txt_i="11432" txt_f="11440">&lt;0.001).</offsets></p><p><offsets xml_i="18667" xml_f="18709" txt_i="11441" txt_f="11483">The unadjusted Cox's regression analysis (</offsets><xref rid="tbl2" ref-type="table"><offsets xml_i="18743" xml_f="18750" txt_i="11483" txt_f="11490">Table 2</offsets></xref><offsets xml_i="18757" xml_f="19246" txt_i="11490" txt_f="11970">) showed that weight loss before radiotherapy (of any category) was significantly associated with a worse overall survival. In addition, we found that the two most severe weight loss categories (&gt;5–10% and &gt;10% weight loss) were significantly associated with a worse disease-specific survival. After adjustment for all previously mentioned potential confounders, &gt;10% weight loss before radiotherapy remained significantly associated with a worse overall (HR 1.7; 95% CI 1.2–2.5; </offsets><italic><offsets xml_i="19254" xml_f="19256" txt_i="11970" txt_f="11972">P=</offsets></italic><offsets xml_i="19265" xml_f="19327" txt_i="11972" txt_f="12034">0.002) and disease-specific survival (HR 2.1; 95% CI 1.2–3.5; </offsets><italic><offsets xml_i="19335" xml_f="19337" txt_i="12034" txt_f="12036">P=</offsets></italic><offsets xml_i="19346" xml_f="19354" txt_i="12036" txt_f="12044">0.007) (</offsets><xref rid="tbl2" ref-type="table"><offsets xml_i="19388" xml_f="19395" txt_i="12044" txt_f="12051">Table 2</offsets></xref><offsets xml_i="19402" xml_f="19404" txt_i="12051" txt_f="12053">).</offsets></p><p><offsets xml_i="19411" xml_f="19604" txt_i="12054" txt_f="12244">In the subgroup of chemoradiotherapy, comorbidity nearly affected the association between weight loss before chemoradiotherapy and overall survival (&gt;10% weight loss HR 3.3, 95% CI 1.7–6.7, </offsets><italic><offsets xml_i="19612" xml_f="19614" txt_i="12244" txt_f="12246">P=</offsets></italic><offsets xml_i="19623" xml_f="19676" txt_i="12246" txt_f="12296">0.001; &gt;5–10% weight loss HR 2.3, 95% CI 1.3–4.2, </offsets><italic><offsets xml_i="19684" xml_f="19686" txt_i="12296" txt_f="12298">P=</offsets></italic><offsets xml_i="19695" xml_f="19742" txt_i="12298" txt_f="12345">0.005; ⩽5% weight loss HR 1.8; 95% CI 1.0–3.2; </offsets><italic><offsets xml_i="19750" xml_f="19752" txt_i="12345" txt_f="12347">P=</offsets></italic><offsets xml_i="19761" xml_f="19845" txt_i="12347" txt_f="12431">0.041). Comorbidity was not significantly associated with disease-specific survival.</offsets></p></sec><sec><title><offsets xml_i="19867" xml_f="19898" txt_i="12433" txt_f="12464">Weight loss during radiotherapy</offsets></title><p><offsets xml_i="19909" xml_f="20174" txt_i="12465" txt_f="12730">Critical weight loss during radiotherapy was observed in 57% of patients. Mean weight loss during radiotherapy was 4.1 (±4.7) kg, which corresponded to 5.4 (±6.1)% of body weight. On average, patients with critical weight loss lost 9.0 (±4.8)% of their body weight.</offsets></p><p><offsets xml_i="20181" xml_f="20340" txt_i="12731" txt_f="12890">Patients with critical weight loss had lower 5-year overall survival rates than patients without critical weight loss during radiotherapy (survival rates: 62% </offsets><italic><offsets xml_i="20348" xml_f="20350" txt_i="12890" txt_f="12892">vs</offsets></italic><offsets xml_i="20359" xml_f="20374" txt_i="12892" txt_f="12907"> 70% log rank: </offsets><italic><offsets xml_i="20382" xml_f="20384" txt_i="12907" txt_f="12909">P=</offsets></italic><offsets xml_i="20393" xml_f="20499" txt_i="12909" txt_f="13015">0.01). However, the adjusted association was no longer statistically significant (HR 1.1; 95% CI 0.9–1.4; </offsets><italic><offsets xml_i="20507" xml_f="20509" txt_i="13015" txt_f="13017">P=</offsets></italic><offsets xml_i="20518" xml_f="20526" txt_i="13017" txt_f="13025">0.295) (</offsets><xref rid="tbl3" ref-type="table"><offsets xml_i="20560" xml_f="20567" txt_i="13025" txt_f="13032">Table 3</offsets></xref><offsets xml_i="20574" xml_f="20576" txt_i="13032" txt_f="13034">).</offsets></p><p><offsets xml_i="20583" xml_f="20758" txt_i="13035" txt_f="13210">The 5-year disease-specific survival rate for patients with critical weight loss was 82%, compared with 89% for patients without critical weight loss (HR 1.7; 95% CI 1.2–2.3; </offsets><italic><offsets xml_i="20766" xml_f="20768" txt_i="13210" txt_f="13212">P=</offsets></italic><offsets xml_i="20777" xml_f="20784" txt_i="13212" txt_f="13219">0.001; </offsets><xref ref-type="fig" rid="fig3"><offsets xml_i="20816" xml_f="20824" txt_i="13219" txt_f="13227">Figure 3</offsets></xref><offsets xml_i="20831" xml_f="21012" txt_i="13227" txt_f="13408">). After adjustment for all confounders, disease-specific survival was still significantly worse for patients with critical weight loss during radiotherapy (HR 1.7; 95% CI 1.2–2.4; </offsets><italic><offsets xml_i="21020" xml_f="21022" txt_i="13408" txt_f="13410">P=</offsets></italic><offsets xml_i="21031" xml_f="21039" txt_i="13410" txt_f="13418">0.004) (</offsets><xref rid="tbl3" ref-type="table"><offsets xml_i="21073" xml_f="21080" txt_i="13418" txt_f="13425">Table 3</offsets></xref><offsets xml_i="21087" xml_f="21089" txt_i="13425" txt_f="13427">).</offsets></p><p><offsets xml_i="21096" xml_f="21283" txt_i="13428" txt_f="13615">In the subgroup of chemoradiotherapy, all patients who died because of head and neck cancer had critical weight loss during therapy. Therefore, no further subgroup analyses were possible.</offsets></p><p><offsets xml_i="21290" xml_f="21353" txt_i="13616" txt_f="13679">Patients who were excluded because of missing baseline weight (</offsets><xref ref-type="fig" rid="fig1"><offsets xml_i="21385" xml_f="21393" txt_i="13679" txt_f="13687">Figure 1</offsets></xref><offsets xml_i="21400" xml_f="21486" txt_i="13687" txt_f="13773">), had a shorter overall survival time compared with the included patients (log rank: </offsets><italic><offsets xml_i="21494" xml_f="21496" txt_i="13773" txt_f="13775">P=</offsets></italic><offsets xml_i="21505" xml_f="21571" txt_i="13775" txt_f="13841">0.009). Disease-specific survival was not significantly different.</offsets></p></sec></sec><sec sec-type="discussion"><title><offsets xml_i="21621" xml_f="21631" txt_i="13844" txt_f="13854">Discussion</offsets></title><p><offsets xml_i="21642" xml_f="21753" txt_i="13855" txt_f="13966">Weight loss as a consequence of (chemo)radiotherapy is a common problem in patients with head and neck cancer (</offsets><xref ref-type="bibr" rid="bib16"><offsets xml_i="21787" xml_f="21795" txt_i="13966" txt_f="13974">Langius </offsets><italic><offsets xml_i="21803" xml_f="21808" txt_i="13974" txt_f="13979">et al</offsets></italic><offsets xml_i="21817" xml_f="21823" txt_i="13979" txt_f="13985">, 2013</offsets></xref><offsets xml_i="21830" xml_f="21959" txt_i="13985" txt_f="14114">). However, little is known about its prognostic effect on disease-specific survival. This study shows that critical weight loss </offsets><italic><offsets xml_i="21967" xml_f="21973" txt_i="14114" txt_f="14120">during</offsets></italic><offsets xml_i="21982" xml_f="22086" txt_i="14120" txt_f="14224"> radiotherapy is independently associated with a 1.7 times higher risk of dying of head and neck cancer.</offsets></p><p><offsets xml_i="22093" xml_f="22150" txt_i="14225" txt_f="14282">Moreover, this large study demonstrates that weight loss </offsets><italic><offsets xml_i="22158" xml_f="22164" txt_i="14282" txt_f="14288">before</offsets></italic><offsets xml_i="22173" xml_f="22255" txt_i="14288" txt_f="14370"> radiotherapy is also independently associated with almost two-fold risk of dying.</offsets></p><p><offsets xml_i="22262" xml_f="22427" txt_i="14371" txt_f="14536">The association between pre-treatment weight loss and disease-specific survival has been investigated only once in a subgroup of patients with head and neck cancer (</offsets><xref ref-type="bibr" rid="bib30"><offsets xml_i="22461" xml_f="22470" txt_i="14536" txt_f="14545">Regueiro </offsets><italic><offsets xml_i="22478" xml_f="22483" txt_i="14545" txt_f="14550">et al</offsets></italic><offsets xml_i="22492" xml_f="22498" txt_i="14550" txt_f="14556">, 1994</offsets></xref><offsets xml_i="22505" xml_f="22872" txt_i="14556" txt_f="14923">). In that study, weight loss before radiotherapy was an independent predictor for disease-specific survival in patients with cancer of the oropharynx, with a hazard ratio of 2.3. We found comparable results in this mixed group of head and neck cancer patients, and this finding therefore can now be extended to the entire group of patients with head and neck cancer.</offsets></p><p><offsets xml_i="22879" xml_f="22973" txt_i="14924" txt_f="15018">Recently, two studies investigated the impact of weight loss during radiotherapy on survival (</offsets><xref ref-type="bibr" rid="bib26"><offsets xml_i="23007" xml_f="23011" txt_i="15018" txt_f="15022">Pai </offsets><italic><offsets xml_i="23019" xml_f="23024" txt_i="15022" txt_f="15027">et al</offsets></italic><offsets xml_i="23033" xml_f="23039" txt_i="15027" txt_f="15033">, 2012</offsets></xref><offsets xml_i="23046" xml_f="23048" txt_i="15033" txt_f="15035">; </offsets><xref ref-type="bibr" rid="bib7"><offsets xml_i="23081" xml_f="23085" txt_i="15035" txt_f="15039">Cho </offsets><italic><offsets xml_i="23093" xml_f="23098" txt_i="15039" txt_f="15044">et al</offsets></italic><offsets xml_i="23107" xml_f="23113" txt_i="15044" txt_f="15050">, 2013</offsets></xref><offsets xml_i="23120" xml_f="23139" txt_i="15050" txt_f="15069">). In the study of </offsets><xref ref-type="bibr" rid="bib26"><offsets xml_i="23173" xml_f="23177" txt_i="15069" txt_f="15073">Pai </offsets><italic><offsets xml_i="23185" xml_f="23190" txt_i="15073" txt_f="15078">et al</offsets></italic><offsets xml_i="23199" xml_f="23206" txt_i="15078" txt_f="15085"> (2012)</offsets></xref><offsets xml_i="23213" xml_f="23332" txt_i="15085" txt_f="15204">, weight loss during radiotherapy was an independent prognostic factor for locoregional control, but not for survival. </offsets><xref ref-type="bibr" rid="bib7"><offsets xml_i="23365" xml_f="23369" txt_i="15204" txt_f="15208">Cho </offsets><italic><offsets xml_i="23377" xml_f="23382" txt_i="15208" txt_f="15213">et al</offsets></italic><offsets xml_i="23391" xml_f="23398" txt_i="15213" txt_f="15220"> (2013)</offsets></xref><offsets xml_i="23405" xml_f="23637" txt_i="15220" txt_f="15452"> found weight loss of ⩾10% during and 1 year after treatment as an independent prognostic factor for disease-free survival (hazard ratio 2.2), but not for overall survival, in patient with cancers of the oral cavity and oropharynx).</offsets></p><p><offsets xml_i="23644" xml_f="23686" txt_i="15453" txt_f="15495">Our results are in line with those of Cho </offsets><italic><offsets xml_i="23694" xml_f="23699" txt_i="15495" txt_f="15500">et al</offsets></italic><offsets xml_i="23708" xml_f="24201" txt_i="15500" txt_f="15993"> (2013). We examined the association of critical weight loss during radiotherapy and 5-year overall and disease-specific survival. In the unadjusted analysis, we found that critical weight loss during radiotherapy was significantly associated with a worse 5-year overall survival, but this association disappeared after adjusting for other relevant prognostic factors. However, critical weight loss during radiotherapy was an independent prognostic factor for 5-year disease-specific survival.</offsets></p><p><offsets xml_i="24208" xml_f="24534" txt_i="15994" txt_f="16320">The observation that patients with critical weight loss during radiotherapy have worse disease-specific survival suggests that treatment is less effective in this patient group. The direct effect of radiotherapy on cancer cell death through irreparable DNA damage is intensified by stimulating an anti-tumour immune response (</offsets><xref ref-type="bibr" rid="bib39"><offsets xml_i="24568" xml_f="24571" txt_i="16320" txt_f="16323">Vu </offsets><italic><offsets xml_i="24579" xml_f="24584" txt_i="16323" txt_f="16328">et al</offsets></italic><offsets xml_i="24593" xml_f="24599" txt_i="16328" txt_f="16334">, 2010</offsets></xref><offsets xml_i="24606" xml_f="24608" txt_i="16334" txt_f="16336">; </offsets><xref ref-type="bibr" rid="bib15"><offsets xml_i="24642" xml_f="24649" txt_i="16336" txt_f="16343">Kwilas </offsets><italic><offsets xml_i="24657" xml_f="24662" txt_i="16343" txt_f="16348">et al</offsets></italic><offsets xml_i="24671" xml_f="24677" txt_i="16348" txt_f="16354">, 2012</offsets></xref><offsets xml_i="24684" xml_f="24686" txt_i="16354" txt_f="16356">; </offsets><xref ref-type="bibr" rid="bib34"><offsets xml_i="24720" xml_f="24725" txt_i="16356" txt_f="16361">Tong </offsets><italic><offsets xml_i="24733" xml_f="24738" txt_i="16361" txt_f="16366">et al</offsets></italic><offsets xml_i="24747" xml_f="24753" txt_i="16366" txt_f="16372">, 2012</offsets></xref><offsets xml_i="24760" xml_f="24997" txt_i="16372" txt_f="16609">). The poor response to treatment might be due to an impaired immune response as a consequence of insufficient food intake in the malnourished patients. The immune system is highly dependent upon an adequate availability of amino acids (</offsets><xref ref-type="bibr" rid="bib18"><offsets xml_i="25031" xml_f="25034" txt_i="16609" txt_f="16612">Li </offsets><italic><offsets xml_i="25042" xml_f="25047" txt_i="16612" txt_f="16617">et al</offsets></italic><offsets xml_i="25056" xml_f="25062" txt_i="16617" txt_f="16623">, 2007</offsets></xref><offsets xml_i="25069" xml_f="25124" txt_i="16623" txt_f="16678">) and specific vitamins, minerals, and trace elements (</offsets><xref ref-type="bibr" rid="bib41"><offsets xml_i="25158" xml_f="25170" txt_i="16678" txt_f="16690">Wintergerst </offsets><italic><offsets xml_i="25178" xml_f="25183" txt_i="16690" txt_f="16695">et al</offsets></italic><offsets xml_i="25192" xml_f="25198" txt_i="16695" txt_f="16701">, 2007</offsets></xref><offsets xml_i="25205" xml_f="25207" txt_i="16701" txt_f="16703">; </offsets><xref ref-type="bibr" rid="bib23"><offsets xml_i="25241" xml_f="25246" txt_i="16703" txt_f="16708">Mora </offsets><italic><offsets xml_i="25254" xml_f="25259" txt_i="16708" txt_f="16713">et al</offsets></italic><offsets xml_i="25268" xml_f="25274" txt_i="16713" txt_f="16719">, 2008</offsets></xref><offsets xml_i="25281" xml_f="25387" txt_i="16719" txt_f="16825">). Deficiency of nutrients alters the immune response, even when the deficiency state is relatively mild (</offsets><xref ref-type="bibr" rid="bib6"><offsets xml_i="25420" xml_f="25433" txt_i="16825" txt_f="16838">Chandra, 2002</offsets></xref><offsets xml_i="25440" xml_f="25792" txt_i="16838" txt_f="17190">). We attempted to link critical weight loss and immunity in our own series. It was previously demonstrated that a severe deficiency of peripheral blood iNKT cells in patients with head and neck cancer was significantly related to poor clinical outcome, suggesting their critical contribution to anti-tumour responses in head and neck cancer patients (</offsets><xref ref-type="bibr" rid="bib22"><offsets xml_i="25826" xml_f="25834" txt_i="17190" txt_f="17198">Molling </offsets><italic><offsets xml_i="25842" xml_f="25847" txt_i="17198" txt_f="17203">et al</offsets></italic><offsets xml_i="25856" xml_f="25862" txt_i="17203" txt_f="17209">, 2007</offsets></xref><offsets xml_i="25869" xml_f="25875" txt_i="17209" txt_f="17215">). We </offsets><italic><offsets xml_i="25883" xml_f="25891" txt_i="17215" txt_f="17223">post hoc</offsets></italic><offsets xml_i="25900" xml_f="26058" txt_i="17223" txt_f="17378"> analysed the relation between weight loss and iNKT cells and found that patients with &gt;5% weight loss had significantly lower numbers of T cells (722±306 </offsets><italic><offsets xml_i="26066" xml_f="26068" txt_i="17378" txt_f="17380">vs</offsets></italic><offsets xml_i="26077" xml_f="26135" txt_i="17380" txt_f="17438"> 1162±580T cells per μl in patients with ⩽5% weight loss, </offsets><italic><offsets xml_i="26143" xml_f="26145" txt_i="17438" txt_f="17440">P=</offsets></italic><offsets xml_i="26154" xml_f="26268" txt_i="17440" txt_f="17551">0.021), and more often a low (&lt;25th percentile) iNKT cell level compared to patients with ⩽5% weight loss (55% </offsets><italic><offsets xml_i="26276" xml_f="26278" txt_i="17551" txt_f="17553">vs</offsets></italic><offsets xml_i="26287" xml_f="26305" txt_i="17553" txt_f="17571"> 15% of patients, </offsets><italic><offsets xml_i="26313" xml_f="26315" txt_i="17571" txt_f="17573">P=</offsets></italic><offsets xml_i="26324" xml_f="26495" txt_i="17573" txt_f="17744">0.004). Although this analysis strengthened our hypothesis, further investigation of the impact of malnutrition on immune response in cancer patients is clearly warranted.</offsets></p><p><offsets xml_i="26502" xml_f="26776" txt_i="17745" txt_f="18019">Weight loss during radiotherapy frequently occurs in patients with head and neck cancer. In our study, the prevalence of critical weight loss during and shortly after radiotherapy was 57%. Several different definitions are used to define malnutrition or severe weight loss (</offsets><xref ref-type="bibr" rid="bib21"><offsets xml_i="26810" xml_f="26818" txt_i="18019" txt_f="18027">Meijers </offsets><italic><offsets xml_i="26826" xml_f="26831" txt_i="18027" txt_f="18032">et al</offsets></italic><offsets xml_i="26840" xml_f="26846" txt_i="18032" txt_f="18038">, 2010</offsets></xref><offsets xml_i="26853" xml_f="27076" txt_i="18038" txt_f="18261">). Our cutoff points for critical weight loss during radiotherapy were based on the international consensus statement of the Academy of Nutrition and Dietetics and the American Society for Parenteral and Enteral Nutrition (</offsets><xref ref-type="bibr" rid="bib40"><offsets xml_i="27110" xml_f="27116" txt_i="18261" txt_f="18267">White </offsets><italic><offsets xml_i="27124" xml_f="27129" txt_i="18267" txt_f="18272">et al</offsets></italic><offsets xml_i="27138" xml_f="27144" txt_i="18272" txt_f="18278">, 2012</offsets></xref><offsets xml_i="27151" xml_f="27238" txt_i="18278" txt_f="18365">). Lower or higher cutoff points could probably decrease or increase the hazard ratios.</offsets></p><p><offsets xml_i="27245" xml_f="27529" txt_i="18366" txt_f="18650">Although we did not reach weight stabilisation during radiotherapy with our nutritional policy, critical weight loss can be avoided. Several studies in patients with head and neck cancer showed that nutritional therapy can be effective in stabilising body weight during radiotherapy (</offsets><xref ref-type="bibr" rid="bib13"><offsets xml_i="27563" xml_f="27572" txt_i="18650" txt_f="18659">Isenring </offsets><italic><offsets xml_i="27580" xml_f="27585" txt_i="18659" txt_f="18664">et al</offsets></italic><offsets xml_i="27594" xml_f="27600" txt_i="18664" txt_f="18670">, 2004</offsets></xref><offsets xml_i="27607" xml_f="27609" txt_i="18670" txt_f="18672">; </offsets><xref ref-type="bibr" rid="bib19"><offsets xml_i="27643" xml_f="27649" txt_i="18672" txt_f="18678">Macia </offsets><italic><offsets xml_i="27657" xml_f="27662" txt_i="18678" txt_f="18683">et al</offsets></italic><offsets xml_i="27671" xml_f="27677" txt_i="18683" txt_f="18689">, 1991</offsets></xref><offsets xml_i="27684" xml_f="27971" txt_i="18689" txt_f="18976">). Our results may cautiously suggest that preventing malnutrition by nutritional therapy might exert a positive influence on cause-specific survival. However, intervention studies are needed to answer the important question if prevention of weight loss indeed has an impact on survival.</offsets></p><p><offsets xml_i="27978" xml_f="28513" txt_i="18977" txt_f="19512">Most of the previous studies on the association of pre-treatment weight loss and overall survival performed only unadjusted analyses. The drawback of unadjusted survival analyses is that confounders may disturb the relation between weight loss during radiotherapy and survival. Thus, significant differences in the unadjusted analyses may result from other confounding variables, such as tumour location and disease stage. A strength of the present study is that herein adequate adjustment for relevant prognostic factors was possible.</offsets></p><p><offsets xml_i="28520" xml_f="29180" txt_i="19513" txt_f="20173">Some limitations of this study should be acknowledged. First, we had to exclude 172 patients (13%) for the analysis of weight loss during radiotherapy, and these patients had a worse overall survival compared with the included patients. It is unknown whether the exclusion of those patients has affected our results, that is, the absence of an association between critical weight loss during radiotherapy and overall survival. Second, the dose distribution of radiotherapy may influence the amount of weight loss during radiotherapy. Given the number of patients we did not delineate organs at risk for weight loss, but we used target volume in general (local </offsets><italic><offsets xml_i="29188" xml_f="29190" txt_i="20173" txt_f="20175">vs</offsets></italic><offsets xml_i="29199" xml_f="29216" txt_i="20175" txt_f="20192"> unilateral neck </offsets><italic><offsets xml_i="29224" xml_f="29226" txt_i="20192" txt_f="20194">vs</offsets></italic><offsets xml_i="29235" xml_f="29731" txt_i="20194" txt_f="20690"> bilateral neck) as a surrogate for dose to the swallowing structures. In another analysis (unpublished data), we found that this provides useful information with regard to the dose distribution to the most important organs at risk. Third, despite the adjustment for important confounding variables, we were not able to adjust for comorbidity in the entire group of patients. We used the WHO performance score. In the subgroup of patients receiving chemoradiotherapy, results of the ACE-27 test (</offsets><xref ref-type="bibr" rid="bib27"><offsets xml_i="29765" xml_f="29787" txt_i="20690" txt_f="20712">Paleri and Wight, 2002</offsets></xref><offsets xml_i="29794" xml_f="30458" txt_i="20712" txt_f="21376">) were available and used for a subanalysis. In contrast to what we expected, comorbidity did not alter the effect of weight loss on survival. Fourth, just as in other studies, pre-treatment weight loss had to be recalled because patients were newly referred to the hospital. We suppose that patient might have underreported their weight loss, especially patients with the smallest amounts of weight loss who where therefore classified into the reference group. This might have lead to underestimation of the prognostic effects on survival. On the other hand, it has been demonstrated that self-reported weight is a highly sensitive method to define malnutrition (</offsets><xref ref-type="bibr" rid="bib12"><offsets xml_i="30492" xml_f="30502" txt_i="21376" txt_f="21386">Haverkort </offsets><italic><offsets xml_i="30510" xml_f="30515" txt_i="21386" txt_f="21391">et al</offsets></italic><offsets xml_i="30524" xml_f="30530" txt_i="21391" txt_f="21397">, 2012</offsets></xref><offsets xml_i="30537" xml_f="30902" txt_i="21397" txt_f="21762">). The weight loss categories in our study had large intervals, so small differences in weight loss estimation would not have lead to other classification. We therefore deem that the results might marginally be influenced by the recall method, and if so, the extent of the association between weight loss before radiotherapy and survival is probably underestimated.</offsets></p><p><offsets xml_i="30909" xml_f="31189" txt_i="21763" txt_f="22043">In conclusion, weight loss both before and during radiotherapy are important prognostic indicators for 5-year disease-specific survival in patients with head and neck cancer. Randomised studies into the prognostic effect of nutritional intervention during radiotherapy are needed.</offsets></p></sec></body><back><ack><p></p></ack><fn-group><fn><p>This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.</p></fn></fn-group><ref-list><ref id="bib1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Argiris</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Forastiere</surname><given-names>A</given-names></name></person-group><year>2004</year><article-title>Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck</article-title><source>Cancer</source><volume>101</volume><fpage>2222</fpage><lpage>2229</lpage><pub-id pub-id-type="pmid">15452834</pub-id></mixed-citation></ref><ref id="bib2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baracos</surname><given-names>VE</given-names></name></person-group><year>2006</year><article-title>Cancer-associated cachexia and underlying biological mechanisms</article-title><source>Annu Rev Nutr</source><volume>26</volume><fpage>435</fpage><lpage>461</lpage><pub-id pub-id-type="pmid">16602932</pub-id></mixed-citation></ref><ref id="bib3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brookes</surname><given-names>GB</given-names></name></person-group><year>1985</year><article-title>Nutritional status-a prognostic indicator in head and neck cancer</article-title><source>Otolaryngol Head Neck Surg</source><volume>93</volume><fpage>69</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">3920627</pub-id></mixed-citation></ref><ref id="bib4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Capuano</surname><given-names>G</given-names></name><name><surname>Gentile</surname><given-names>PC</given-names></name><name><surname>Bianciardi</surname><given-names>F</given-names></name><name><surname>Tosti</surname><given-names>M</given-names></name><name><surname>Palladino</surname><given-names>A</given-names></name><name><surname>Di</surname><given-names>PM</given-names></name></person-group><year>2010</year><article-title>Prevalence and influence of malnutrition on quality of life and performance status in patients with locally advanced head and neck cancer before treatment</article-title><source>Support Care Cancer</source><volume>18</volume><fpage>433</fpage><lpage>437</lpage><pub-id pub-id-type="pmid">19562384</pub-id></mixed-citation></ref><ref id="bib5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Capuano</surname><given-names>G</given-names></name><name><surname>Grosso</surname><given-names>A</given-names></name><name><surname>Gentile</surname><given-names>PC</given-names></name><name><surname>Battista</surname><given-names>M</given-names></name><name><surname>Bianciardi</surname><given-names>F</given-names></name><name><surname>Di</surname><given-names>PA</given-names></name><name><surname>Pavese</surname><given-names>I</given-names></name><name><surname>Satta</surname><given-names>F</given-names></name><name><surname>Tosti</surname><given-names>M</given-names></name><name><surname>Palladino</surname><given-names>A</given-names></name><name><surname>Coiro</surname><given-names>G</given-names></name><name><surname>Di</surname><given-names>PM</given-names></name></person-group><year>2008</year><article-title>Influence of weight loss on outcomes in patients with head and neck cancer undergoing concomitant chemoradiotherapy</article-title><source>Head Neck</source><volume>30</volume><fpage>503</fpage><lpage>508</lpage><pub-id pub-id-type="pmid">18098310</pub-id></mixed-citation></ref><ref id="bib6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chandra</surname><given-names>RK</given-names></name></person-group><year>2002</year><article-title>Nutrition and the immune system from birth to old age</article-title><source>Eur J Clin Nutr</source><volume>56</volume><supplement>(Suppl 3</supplement><fpage>S73</fpage><lpage>S76</lpage><pub-id pub-id-type="pmid">12142969</pub-id></mixed-citation></ref><ref id="bib7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>YW</given-names></name><name><surname>Roh</surname><given-names>JL</given-names></name><name><surname>Jung</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>SB</given-names></name><name><surname>Lee</surname><given-names>SW</given-names></name><name><surname>Choi</surname><given-names>SH</given-names></name><name><surname>Nam</surname><given-names>SY</given-names></name><name><surname>Kim</surname><given-names>SY</given-names></name><name><surname>Kim</surname><given-names>SY</given-names></name></person-group><year>2013</year><article-title>Prediction of posttreament significant body weight loss and its correlation with disease-free survival in patients with oral squamous cell carcinomas</article-title><source>Nutr Cancer</source><volume>65</volume><fpage>417</fpage><lpage>423</lpage><pub-id pub-id-type="pmid">23530641</pub-id></mixed-citation></ref><ref id="bib8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Cassia Braga</surname><given-names>RK</given-names></name><name><surname>Kowalski</surname><given-names>LP</given-names></name><name><surname>Latorre</surname><given-names>MR</given-names></name></person-group><year>2003</year><article-title>Perioperative complications, comorbidities, and survival in oral or oropharyngeal cancer</article-title><source>Arch Otolaryngol Head Neck Surg</source><volume>129</volume><fpage>219</fpage><lpage>228</lpage><pub-id pub-id-type="pmid">12578453</pub-id></mixed-citation></ref><ref id="bib9"><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Edge</surname><given-names>SB</given-names></name><name><surname>Byrd</surname><given-names>DR</given-names></name><name><surname>Compton</surname><given-names>CC</given-names></name><name><surname>Fritz</surname><given-names>AG</given-names></name><name><surname>Green</surname><given-names>FL</given-names></name><name><surname>Trotti</surname><given-names>A</given-names></name></person-group><year>2010</year><source>AJCC Cancer Staging Manual</source><publisher-name>Springer</publisher-name></mixed-citation></ref><ref id="bib10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ehrsson</surname><given-names>YT</given-names></name><name><surname>Hellstrom</surname><given-names>PM</given-names></name><name><surname>Brismar</surname><given-names>K</given-names></name><name><surname>Sharp</surname><given-names>L</given-names></name><name><surname>Langius-Eklof</surname><given-names>A</given-names></name><name><surname>Laurell</surname><given-names>G</given-names></name></person-group><year>2010</year><article-title>Explorative study on the predictive value of systematic inflammatory and metabolic markers on weight loss in head and neck cancer patients undergoing radiotherapy</article-title><source>Support Care Cancer</source><volume>18</volume><fpage>1385</fpage><lpage>1391</lpage><pub-id pub-id-type="pmid">19830461</pub-id></mixed-citation></ref><ref id="bib11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frank</surname><given-names>E</given-names></name><name><surname>Dunlop</surname><given-names>AL</given-names></name></person-group><year>2000</year><article-title>What does a patient's outfit weight</article-title><source>Fam Med</source><volume>32</volume><fpage>595</fpage><lpage>596</lpage><pub-id pub-id-type="pmid">11039142</pub-id></mixed-citation></ref><ref id="bib12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haverkort</surname><given-names>EB</given-names></name><name><surname>De Haan</surname><given-names>RJ</given-names></name><name><surname>Binnekade</surname><given-names>JM</given-names></name><name><surname>Van Bokhorst-de van der Schueren</surname><given-names>MA</given-names></name></person-group><year>2012</year><article-title>Self-reporting of height and weight: valid and reliable identification of malnutrition in preoperative patients</article-title><source>Am J Surg</source><volume>203</volume><fpage>700</fpage><lpage>707</lpage><pub-id pub-id-type="pmid">22365153</pub-id></mixed-citation></ref><ref id="bib13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Isenring</surname><given-names>EA</given-names></name><name><surname>Capra</surname><given-names>S</given-names></name><name><surname>Bauer</surname><given-names>JD</given-names></name></person-group><year>2004</year><article-title>Nutrition intervention is beneficial in oncology outpatients receiving radiotherapy to the gastrointestinal or head and neck area</article-title><source>Br J Cancer</source><volume>91</volume><fpage>447</fpage><lpage>452</lpage><pub-id pub-id-type="pmid">15226773</pub-id></mixed-citation></ref><ref id="bib14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jager-Wittenaar</surname><given-names>H</given-names></name><name><surname>Dijkstra</surname><given-names>PU</given-names></name><name><surname>Vissink</surname><given-names>A</given-names></name><name><surname>van der Laan</surname><given-names>BF</given-names></name><name><surname>van Oort</surname><given-names>RP</given-names></name><name><surname>Roodenburg</surname><given-names>JL</given-names></name></person-group><year>2007</year><article-title>Critical weight loss in head and neck cancer-prevalence and risk factors at diagnosis: an explorative study</article-title><source>Support Care Cancer</source><volume>15</volume><fpage>1045</fpage><lpage>1050</lpage><pub-id pub-id-type="pmid">17277925</pub-id></mixed-citation></ref><ref id="bib15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwilas</surname><given-names>AR</given-names></name><name><surname>Donahue</surname><given-names>RN</given-names></name><name><surname>Bernstein</surname><given-names>MB</given-names></name><name><surname>Hodge</surname><given-names>JW</given-names></name></person-group><year>2012</year><article-title>In the field: exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer</article-title><source>Front Oncol</source><volume>2</volume><fpage>104</fpage><pub-id pub-id-type="pmid">22973551</pub-id></mixed-citation></ref><ref id="bib16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langius</surname><given-names>JA</given-names></name><name><surname>van Dijk</surname><given-names>AM</given-names></name><name><surname>Doornaert</surname><given-names>P</given-names></name><name><surname>Kruizenga</surname><given-names>HM</given-names></name><name><surname>Langendijk</surname><given-names>JA</given-names></name><name><surname>Leemans</surname><given-names>CR</given-names></name><name><surname>Weijs</surname><given-names>PJ</given-names></name><name><surname>Verdonck-de</surname><given-names>LI</given-names></name></person-group><year>2013</year><article-title>More than 10% weight loss in head and neck cancer patients during radiotherapy is independently associated with deterioration in quality of life</article-title><source>Nutr Cancer</source><volume>65</volume><fpage>76</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">23368916</pub-id></mixed-citation></ref><ref id="bib17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langius</surname><given-names>JAE</given-names></name><name><surname>Doornaert</surname><given-names>P</given-names></name><name><surname>Spreeuwenberg</surname><given-names>MD</given-names></name><name><surname>Langendijk</surname><given-names>JA</given-names></name><name><surname>Leemans</surname><given-names>CR</given-names></name><name><surname>Schueren</surname><given-names>MA</given-names></name></person-group><year>2010</year><article-title>Radiotherapy on the neck nodes predicts severe weight loss in patients with early stage laryngeal cancer</article-title><source>Radiother Oncol</source><volume>97</volume><fpage>80</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">20223540</pub-id></mixed-citation></ref><ref id="bib18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Yin</surname><given-names>YL</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Kim</surname><given-names>SW</given-names></name><name><surname>Wu</surname><given-names>G</given-names></name></person-group><year>2007</year><article-title>Amino acids and immune function</article-title><source>Br J Nutr</source><volume>98</volume><fpage>237</fpage><lpage>252</lpage><pub-id pub-id-type="pmid">17403271</pub-id></mixed-citation></ref><ref id="bib19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Macia</surname><given-names>E</given-names></name><name><surname>Moran</surname><given-names>J</given-names></name><name><surname>Santos</surname><given-names>J</given-names></name><name><surname>Blanco</surname><given-names>M</given-names></name><name><surname>Mahedero</surname><given-names>G</given-names></name><name><surname>Salas</surname><given-names>J</given-names></name></person-group><year>1991</year><article-title>Nutritional evaluation and dietetic care in cancer patients treated with radiotherapy: prospective study</article-title><source>Nutrition</source><volume>7</volume><fpage>205</fpage><lpage>209</lpage><pub-id pub-id-type="pmid">1802209</pub-id></mixed-citation></ref><ref id="bib20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehanna</surname><given-names>H</given-names></name><name><surname>West</surname><given-names>CM</given-names></name><name><surname>Nutting</surname><given-names>C</given-names></name><name><surname>Paleri</surname><given-names>V</given-names></name></person-group><year>2010</year><article-title>Head and neck cancer—Part 2: Treatment and prognostic factors</article-title><source>BMJ</source><volume>341</volume><fpage>c4690</fpage><pub-id pub-id-type="pmid">20876637</pub-id></mixed-citation></ref><ref id="bib21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meijers</surname><given-names>JM</given-names></name><name><surname>van Bokhorst-de van der Schueren</surname><given-names>MA</given-names></name><name><surname>Schols</surname><given-names>JM</given-names></name><name><surname>Soeters</surname><given-names>PB</given-names></name><name><surname>Halfens</surname><given-names>RJ</given-names></name></person-group><year>2010</year><article-title>Defining malnutrition: mission or mission impossible</article-title><source>Nutrition</source><volume>26</volume><fpage>432</fpage><lpage>440</lpage><pub-id pub-id-type="pmid">19954929</pub-id></mixed-citation></ref><ref id="bib22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molling</surname><given-names>JW</given-names></name><name><surname>Langius</surname><given-names>JAE</given-names></name><name><surname>Langendijk</surname><given-names>JA</given-names></name><name><surname>Leemans</surname><given-names>CR</given-names></name><name><surname>Bontkes</surname><given-names>HJ</given-names></name><name><surname>Van Der Vliet</surname><given-names>HJ</given-names></name><name><surname>Von Blomberg</surname><given-names>BM</given-names></name><name><surname>Scheper</surname><given-names>RJ</given-names></name><name><surname>Van Den Eertwegh</surname><given-names>AJ</given-names></name></person-group><year>2007</year><article-title>Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma</article-title><source>J Clin Oncol</source><volume>25</volume><fpage>862</fpage><lpage>868</lpage><pub-id pub-id-type="pmid">17327607</pub-id></mixed-citation></ref><ref id="bib23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mora</surname><given-names>JR</given-names></name><name><surname>Iwata</surname><given-names>M</given-names></name><name><surname>von Andrian</surname><given-names>UH</given-names></name></person-group><year>2008</year><article-title>Vitamin effects on the immune system: vitamins A and D take centre stage</article-title><source>Nat Rev Immunol</source><volume>8</volume><fpage>685</fpage><lpage>698</lpage><pub-id pub-id-type="pmid">19172691</pub-id></mixed-citation></ref><ref id="bib24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nayel</surname><given-names>H</given-names></name><name><surname>el Ghoneimy</surname><given-names>E</given-names></name><name><surname>el Haddad</surname><given-names>S</given-names></name></person-group><year>1992</year><article-title>Impact of nutritional supplementation on treatment delay and morbidity in patients with head and neck tumors treated with irradiation</article-title><source>Nutrition</source><volume>8</volume><fpage>13</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">1562782</pub-id></mixed-citation></ref><ref id="bib25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>TV</given-names></name><name><surname>Yueh</surname><given-names>B</given-names></name></person-group><year>2002</year><article-title>Weight loss predicts mortality after recurrent oral cavity and oropharyngeal carcinomas</article-title><source>Cancer</source><volume>95</volume><fpage>553</fpage><lpage>562</lpage><pub-id pub-id-type="pmid">12209747</pub-id></mixed-citation></ref><ref id="bib26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pai</surname><given-names>PC</given-names></name><name><surname>Chuang</surname><given-names>CC</given-names></name><name><surname>Tseng</surname><given-names>CK</given-names></name><name><surname>Tsang</surname><given-names>NM</given-names></name><name><surname>Chang</surname><given-names>KP</given-names></name><name><surname>Yen</surname><given-names>TC</given-names></name><name><surname>Liao</surname><given-names>CT</given-names></name><name><surname>Hong</surname><given-names>JH</given-names></name><name><surname>Chang</surname><given-names>JT</given-names></name></person-group><year>2012</year><article-title>Impact of pretreatment body mass index on patients with head-and-neck cancer treated with radiation</article-title><source>Int J Radiat Oncol Biol Phys</source><volume>83</volume><fpage>e93</fpage><lpage>e100</lpage><pub-id pub-id-type="pmid">22342298</pub-id></mixed-citation></ref><ref id="bib27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paleri</surname><given-names>V</given-names></name><name><surname>Wight</surname><given-names>RG</given-names></name></person-group><year>2002</year><article-title>Applicability of the Adult Comorbidity Evaluation-27 and the Charlson indexes to assess comorbidity by notes extraction in a cohort of United Kingdom patients with head and neck cancer: a retrospective study</article-title><source>J Laryngol Otol</source><volume>116</volume><fpage>200</fpage><lpage>205</lpage><pub-id pub-id-type="pmid">11893262</pub-id></mixed-citation></ref><ref id="bib28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pedruzzi</surname><given-names>PA</given-names></name><name><surname>Kowalski</surname><given-names>LP</given-names></name><name><surname>Nishimoto</surname><given-names>IN</given-names></name><name><surname>Oliveira</surname><given-names>BV</given-names></name><name><surname>Tironi</surname><given-names>F</given-names></name><name><surname>Ramos</surname><given-names>GH</given-names></name></person-group><year>2008</year><article-title>Analysis of prognostic factors in patients with oropharyngeal squamous cell carcinoma treated with radiotherapy alone or in combination with systemic chemotherapy</article-title><source>Arch Otolaryngol Head Neck Surg</source><volume>134</volume><fpage>1196</fpage><lpage>1204</lpage><pub-id pub-id-type="pmid">19015451</pub-id></mixed-citation></ref><ref id="bib29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pugliano</surname><given-names>FA</given-names></name><name><surname>Piccirillo</surname><given-names>JF</given-names></name><name><surname>Zequeira</surname><given-names>MR</given-names></name><name><surname>Fredrickson</surname><given-names>JM</given-names></name><name><surname>Perez</surname><given-names>CA</given-names></name><name><surname>Simpson</surname><given-names>JR</given-names></name></person-group><year>1999</year><article-title>Symptoms as an index of biologic behavior in head and neck cancer</article-title><source>Otolaryngol Head Neck Surg</source><volume>120</volume><fpage>380</fpage><lpage>386</lpage><pub-id pub-id-type="pmid">10064642</pub-id></mixed-citation></ref><ref id="bib30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Regueiro</surname><given-names>CA</given-names></name><name><surname>Aragon</surname><given-names>G</given-names></name><name><surname>Millan</surname><given-names>I</given-names></name><name><surname>Valcarcel</surname><given-names>FJ</given-names></name><name><surname>de la</surname><given-names>TA</given-names></name><name><surname>Magallon</surname><given-names>R</given-names></name></person-group><year>1994</year><article-title>Prognostic factors for local control, regional control and survival in oropharyngeal squamous cell carcinoma</article-title><source>Eur J Cancer</source><volume>30A</volume><fpage>2060</fpage><lpage>2067</lpage><pub-id pub-id-type="pmid">7857704</pub-id></mixed-citation></ref><ref id="bib31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richey</surname><given-names>LM</given-names></name><name><surname>George</surname><given-names>JR</given-names></name><name><surname>Couch</surname><given-names>ME</given-names></name><name><surname>Kanapkey</surname><given-names>BK</given-names></name><name><surname>Yin</surname><given-names>X</given-names></name><name><surname>Cannon</surname><given-names>T</given-names></name><name><surname>Stewart</surname><given-names>PW</given-names></name><name><surname>Weissler</surname><given-names>MC</given-names></name><name><surname>Shores</surname><given-names>CG</given-names></name></person-group><year>2007</year><article-title>Defining cancer cachexia in head and neck squamous cell carcinoma</article-title><source>Clin Cancer Res</source><volume>13</volume><fpage>6561</fpage><lpage>6567</lpage><pub-id pub-id-type="pmid">18006755</pub-id></mixed-citation></ref><ref id="bib32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silver</surname><given-names>HJ</given-names></name><name><surname>Dietrich</surname><given-names>MS</given-names></name><name><surname>Murphy</surname><given-names>BA</given-names></name></person-group><year>2007</year><article-title>Changes in body mass, energy balance, physical function, and inflammatory state in patients with locally advanced head and neck cancer treated with concurrent chemoradiation after low-dose induction chemotherapy</article-title><source>Head Neck</source><volume>29</volume><fpage>893</fpage><lpage>900</lpage><pub-id pub-id-type="pmid">17405169</pub-id></mixed-citation></ref><ref id="bib33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soeters</surname><given-names>PB</given-names></name><name><surname>Reijven</surname><given-names>PL</given-names></name><name><surname>van Bokhorst-de van der Schueren</surname><given-names>MA</given-names></name><name><surname>Schols</surname><given-names>JM</given-names></name><name><surname>Halfens</surname><given-names>RJ</given-names></name><name><surname>Meijers</surname><given-names>JM</given-names></name><name><surname>van Gemert</surname><given-names>WG</given-names></name></person-group><year>2008</year><article-title>A rational approach to nutritional assessment</article-title><source>Clin Nutr</source><volume>27</volume><fpage>706</fpage><lpage>716</lpage><pub-id pub-id-type="pmid">18783855</pub-id></mixed-citation></ref><ref id="bib34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tong</surname><given-names>CC</given-names></name><name><surname>Kao</surname><given-names>J</given-names></name><name><surname>Sikora</surname><given-names>AG</given-names></name></person-group><year>2012</year><article-title>Recognizing and reversing the immunosuppressive tumor microenvironment of head and neck cancer</article-title><source>Immunol Res</source><volume>54</volume><fpage>266</fpage><lpage>274</lpage><pub-id pub-id-type="pmid">22454102</pub-id></mixed-citation></ref><ref id="bib35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Unsal</surname><given-names>D</given-names></name><name><surname>Mentes</surname><given-names>B</given-names></name><name><surname>Akmansu</surname><given-names>M</given-names></name><name><surname>Uner</surname><given-names>A</given-names></name><name><surname>Oguz</surname><given-names>M</given-names></name><name><surname>Pak</surname><given-names>Y</given-names></name></person-group><year>2006</year><article-title>Evaluation of nutritional status in cancer patients receiving radiotherapy: a prospective study</article-title><source>Am J Clin Oncol</source><volume>29</volume><fpage>183</fpage><lpage>188</lpage><pub-id pub-id-type="pmid">16601440</pub-id></mixed-citation></ref><ref id="bib36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Bokhorst-de van der Schueren</surname><given-names>MAE</given-names></name><name><surname>Van Leeuwen</surname><given-names>PAM</given-names></name><name><surname>Kuik</surname><given-names>DJ</given-names></name><name><surname>Klop</surname><given-names>WMC</given-names></name><name><surname>Sauerwein</surname><given-names>HP</given-names></name><name><surname>Snow</surname><given-names>GB</given-names></name><name><surname>Quak</surname><given-names>JJ</given-names></name></person-group><year>1999</year><article-title>The impact of nutritional status on the prognoses of patients with advanced head and neck cancer</article-title><source>Cancer</source><volume>86</volume><fpage>519</fpage><lpage>527</lpage><pub-id pub-id-type="pmid">10430262</pub-id></mixed-citation></ref><ref id="bib37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Cutsem</surname><given-names>E</given-names></name><name><surname>Arends</surname><given-names>J</given-names></name></person-group><year>2005</year><article-title>The causes and consequences of cancer-associated malnutrition</article-title><source>Eur J Oncol Nurs</source><volume>9</volume><supplement>(Suppl 2</supplement><fpage>S51</fpage><lpage>S63</lpage><pub-id pub-id-type="pmid">16437758</pub-id></mixed-citation></ref><ref id="bib38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Den Broek</surname><given-names>GB</given-names></name><name><surname>Rasch</surname><given-names>CR</given-names></name><name><surname>Pameijer</surname><given-names>FA</given-names></name><name><surname>Peter</surname><given-names>E</given-names></name><name><surname>van den Brekel</surname><given-names>MW</given-names></name><name><surname>Tan</surname><given-names>IB</given-names></name><name><surname>Schornagel</surname><given-names>JH</given-names></name><name><surname>De Bois</surname><given-names>JA</given-names></name><name><surname>Zijp</surname><given-names>LJ</given-names></name><name><surname>Balm</surname><given-names>AJ</given-names></name></person-group><year>2004</year><article-title>Pretreatment probability model for predicting outcome after intraarterial chemoradiation for advanced head and neck carcinoma</article-title><source>Cancer</source><volume>101</volume><fpage>1809</fpage><lpage>1817</lpage><pub-id pub-id-type="pmid">15386309</pub-id></mixed-citation></ref><ref id="bib39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vu</surname><given-names>HL</given-names></name><name><surname>Sikora</surname><given-names>AG</given-names></name><name><surname>Fu</surname><given-names>S</given-names></name><name><surname>Kao</surname><given-names>J</given-names></name></person-group><year>2010</year><article-title>HPV-induced oropharyngeal cancer, immune response and response to therapy</article-title><source>Cancer Lett</source><volume>288</volume><fpage>149</fpage><lpage>155</lpage><pub-id pub-id-type="pmid">19628331</pub-id></mixed-citation></ref><ref id="bib40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>JV</given-names></name><name><surname>Guenter</surname><given-names>P</given-names></name><name><surname>Jensen</surname><given-names>G</given-names></name><name><surname>Malone</surname><given-names>A</given-names></name><name><surname>Schofield</surname><given-names>M</given-names></name></person-group><year>2012</year><article-title>Consensus statement: Academy of Nutrition and Dietetics and American Society for Parenteral and Enteral Nutrition: characteristics recommended for the identification and documentation of adult malnutrition (undernutrition)</article-title><source>JPEN J Parenter Enteral Nutr</source><volume>36</volume><fpage>275</fpage><lpage>283</lpage><pub-id pub-id-type="pmid">22535923</pub-id></mixed-citation></ref><ref id="bib41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wintergerst</surname><given-names>ES</given-names></name><name><surname>Maggini</surname><given-names>S</given-names></name><name><surname>Hornig</surname><given-names>DH</given-names></name></person-group><year>2007</year><article-title>Contribution of selected vitamins and trace elements to immune function</article-title><source>Ann Nutr Metab</source><volume>51</volume><fpage>301</fpage><lpage>323</lpage><pub-id pub-id-type="pmid">17726308</pub-id></mixed-citation></ref></ref-list></back><floats-group><fig id="fig1"><label>Figure 1</label><caption><p>Flowchart.</p></caption><graphic xlink:href="bjc2013458f1"></graphic></fig><fig id="fig2"><label>Figure 2</label><caption><p>Kaplan–Meier survival plot of overall survival by weight loss category before radiotherapy (log-rank test: <italic>P</italic>&lt;0.001).</p></caption><graphic xlink:href="bjc2013458f2"></graphic></fig><fig id="fig3"><label>Figure 3</label><caption><p>Kaplan–Meier survival plot of disease-specific survival by weight loss during radiotherapy (log-rank test: <italic>P=</italic>0.001).</p></caption><graphic xlink:href="bjc2013458f3"></graphic></fig><table-wrap id="tbl1"><label>Table 1</label><caption><title>Patient, tumour, and treatment characteristics</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"></col><col align="center"></col><col align="center"></col><col align="center"></col><col align="center"></col></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"> </th><th align="center" valign="top" charoff="50"><bold>All patients,</bold>
<italic><bold>n</bold></italic>
<bold>(%)</bold></th><th align="center" valign="top" charoff="50"><bold>Alive,</bold>
<italic><bold>n</bold></italic>
<bold>(%)</bold></th><th align="center" valign="top" charoff="50"><bold>Dead,</bold>
<italic><bold>n</bold></italic>
<bold>(%)</bold></th><th align="center" valign="top" charoff="50"><italic><bold>P</bold></italic><bold>-value</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50"> <hr></hr></td><td align="center" valign="top" charoff="50">1340 (100)<hr></hr></td><td align="center" valign="top" charoff="50">869 (65)<hr></hr></td><td align="center" valign="top" charoff="50">471 (35)<hr></hr></td><td align="center" valign="top" charoff="50"> <hr></hr></td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"><bold>Gender</bold><hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">Male</td><td align="center" valign="top" charoff="50">937 (70)</td><td align="center" valign="top" charoff="50">595 (64)</td><td align="center" valign="top" charoff="50">342 (36)</td><td align="center" valign="top" charoff="50">0.11</td></tr><tr><td align="left" valign="top" charoff="50">Female<hr></hr></td><td align="center" valign="top" charoff="50">403 (30)<hr></hr></td><td align="center" valign="top" charoff="50">274 (68)<hr></hr></td><td align="center" valign="top" charoff="50">129 (32)<hr></hr></td><td align="center" valign="top" charoff="50"> <hr></hr></td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"><bold>Age</bold><hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">Mean (s.d.)<hr></hr></td><td align="center" valign="top" charoff="50">61.4±12.0<hr></hr></td><td align="center" valign="top" charoff="50">60.0±11.7<hr></hr></td><td align="center" valign="top" charoff="50">64.1±12.1<hr></hr></td><td align="center" valign="top" charoff="50"><bold>&lt;0.001</bold><hr></hr></td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"><bold>Tumour location</bold><hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">Oral cavity</td><td align="center" valign="top" charoff="50">242 (18)</td><td align="center" valign="top" charoff="50">140 (58)</td><td align="center" valign="top" charoff="50">102 (42)</td><td align="center" valign="top" charoff="50"><bold>&lt;0.001</bold></td></tr><tr><td align="left" valign="top" charoff="50">Oropharynx</td><td align="center" valign="top" charoff="50">310 (23)</td><td align="center" valign="top" charoff="50">189 (61)</td><td align="center" valign="top" charoff="50">121 (39)</td><td align="center" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50">Nasopharynx</td><td align="center" valign="top" charoff="50">47 (4)</td><td align="center" valign="top" charoff="50">33 (70)</td><td align="center" valign="top" charoff="50">14 (30)</td><td align="center" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50">Hypopharynx</td><td align="center" valign="top" charoff="50">74 (6)</td><td align="center" valign="top" charoff="50">22 (30)</td><td align="center" valign="top" charoff="50">52 (70)</td><td align="center" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50">Larynx</td><td align="center" valign="top" charoff="50">436 (33)</td><td align="center" valign="top" charoff="50">321 (74)</td><td align="center" valign="top" charoff="50">115 (26)</td><td align="center" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50">Nasal cavity and paranasal sinuses</td><td align="center" valign="top" charoff="50">106 (8)</td><td align="center" valign="top" charoff="50">77 (73)</td><td align="center" valign="top" charoff="50">29 (27)</td><td align="center" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50">Major salivary glands</td><td align="center" valign="top" charoff="50">75 (6)</td><td align="center" valign="top" charoff="50">53 (71)</td><td align="center" valign="top" charoff="50">22 (29)</td><td align="center" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50">Unknown primary<hr></hr></td><td align="center" valign="top" charoff="50">50 (4)<hr></hr></td><td align="center" valign="top" charoff="50">34 (68)<hr></hr></td><td align="center" valign="top" charoff="50">16 (32)<hr></hr></td><td align="center" valign="top" charoff="50"> <hr></hr></td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"><bold>TNM stage</bold><hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">I</td><td align="center" valign="top" charoff="50">232 (18)</td><td align="center" valign="top" charoff="50">193 (83)</td><td align="center" valign="top" charoff="50">39 (17)</td><td align="center" valign="top" charoff="50"><bold>&lt;0.001</bold></td></tr><tr><td align="left" valign="top" charoff="50">II</td><td align="center" valign="top" charoff="50">269 (21)</td><td align="center" valign="top" charoff="50">206 (77)</td><td align="center" valign="top" charoff="50">63 (23)</td><td align="center" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50">III</td><td align="center" valign="top" charoff="50">232 (18)</td><td align="center" valign="top" charoff="50">159 (68)</td><td align="center" valign="top" charoff="50">73 (32)</td><td align="center" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50">IV<hr></hr></td><td align="center" valign="top" charoff="50">550 (43)<hr></hr></td><td align="center" valign="top" charoff="50">267 (48)<hr></hr></td><td align="center" valign="top" charoff="50">283 (52)<hr></hr></td><td align="center" valign="top" charoff="50"> <hr></hr></td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"><bold>Weight loss before RT</bold><hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">None</td><td align="center" valign="top" charoff="50">911 (70)</td><td align="center" valign="top" charoff="50">642 (71)</td><td align="center" valign="top" charoff="50">269 (30)</td><td align="center" valign="top" charoff="50"><bold>&lt;0.001</bold></td></tr><tr><td align="left" valign="top" charoff="50">⩽5%</td><td align="center" valign="top" charoff="50">215 (16)</td><td align="center" valign="top" charoff="50">126 (59)</td><td align="center" valign="top" charoff="50">89 (41)</td><td align="center" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50">&gt;5–10%</td><td align="center" valign="top" charoff="50">111 (9)</td><td align="center" valign="top" charoff="50">52 (47)</td><td align="center" valign="top" charoff="50">59 (53)</td><td align="center" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50">&gt;10%<hr></hr></td><td align="center" valign="top" charoff="50">69 (5)<hr></hr></td><td align="center" valign="top" charoff="50">29 (42)<hr></hr></td><td align="center" valign="top" charoff="50">40 (58)<hr></hr></td><td align="center" valign="top" charoff="50"> <hr></hr></td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"><bold>WHO performance score</bold><hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">399 (38)</td><td align="center" valign="top" charoff="50">305 (76)</td><td align="center" valign="top" charoff="50">94 (24)</td><td align="center" valign="top" charoff="50"><bold>&lt;0.001</bold></td></tr><tr><td align="left" valign="top" charoff="50">1</td><td align="center" valign="top" charoff="50">533 (51)</td><td align="center" valign="top" charoff="50">333 (63)</td><td align="center" valign="top" charoff="50">200 (37)</td><td align="center" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50">2/3<hr></hr></td><td align="center" valign="top" charoff="50">116 (11)<hr></hr></td><td align="center" valign="top" charoff="50">44 (38)<hr></hr></td><td align="center" valign="top" charoff="50">72 (62)<hr></hr></td><td align="center" valign="top" charoff="50"> <hr></hr></td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"><bold>Treatment modality</bold><hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">RT alone</td><td align="center" valign="top" charoff="50">591 (44)</td><td align="center" valign="top" charoff="50">403 (68)</td><td align="center" valign="top" charoff="50">188 (32)</td><td align="center" valign="top" charoff="50"><bold>0.01</bold></td></tr><tr><td align="left" valign="top" charoff="50">Surgery+RT</td><td align="center" valign="top" charoff="50">485 (36)</td><td align="center" valign="top" charoff="50">313 (65)</td><td align="center" valign="top" charoff="50">172 (35)</td><td align="center" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50">ChemoRT</td><td align="center" valign="top" charoff="50">251 (19)</td><td align="center" valign="top" charoff="50">143 (57)</td><td align="center" valign="top" charoff="50">108 (43)</td><td align="center" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50">Surgery+ChemoRT<hr></hr></td><td align="center" valign="top" charoff="50">13 (1)<hr></hr></td><td align="center" valign="top" charoff="50">10 (77)<hr></hr></td><td align="center" valign="top" charoff="50">3 (23)<hr></hr></td><td align="center" valign="top" charoff="50"> <hr></hr></td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"><bold>RT dose</bold><hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">Median<hr></hr></td><td align="center" valign="top" charoff="50">68<hr></hr></td><td align="center" valign="top" charoff="50">68<hr></hr></td><td align="center" valign="top" charoff="50">70<hr></hr></td><td align="center" valign="top" charoff="50">0.09<hr></hr></td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"><bold>RT on the neck nodes</bold><hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">No</td><td align="center" valign="top" charoff="50">350 (26)</td><td align="center" valign="top" charoff="50">275 (79)</td><td align="center" valign="top" charoff="50">75 (21)</td><td align="center" valign="top" charoff="50"><bold>&lt;0.001</bold></td></tr><tr><td align="left" valign="top" charoff="50">Unilateral</td><td align="center" valign="top" charoff="50">225 (17)</td><td align="center" valign="top" charoff="50">162 (72)</td><td align="center" valign="top" charoff="50">63 (28)</td><td align="center" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50">Bilateral</td><td align="center" valign="top" charoff="50">762 (57)</td><td align="center" valign="top" charoff="50">432 (57)</td><td align="center" valign="top" charoff="50">330 (43)</td><td align="center" valign="top" charoff="50"> </td></tr></tbody></table><table-wrap-foot><fn id="t1-fn1"><p>Abbreviations: RT=radiotherapy; s.d.=standard deviation; TNM=tumour, node, metastasis; WHO=world health organisation.</p></fn><fn id="t1-fn2"><p><italic>P</italic>-values &lt;0.05 are shown in bold. <italic>P</italic>-values were obtained by independent <italic>t-</italic>test or <italic>χ</italic><sup>2</sup> tests.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl2"><label>Table 2</label><caption><title>Cox regression analyses of the association between weight loss before radiotherapy and 5-year overall and disease-specific survival</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"></col><col align="char" char="("></col><col align="center"></col><col align="char" char="("></col><col align="center"></col></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"> <hr></hr></th><th colspan="2" align="center" valign="top" char="(" charoff="50"><bold>Crude model</bold><hr></hr></th><th colspan="2" align="center" valign="top" char="(" charoff="50"><bold>Adjusted model</bold><xref ref-type="fn" rid="t2-fn3">a</xref><hr></hr></th></tr><tr><th align="left" valign="top" charoff="50"> </th><th align="char" valign="top" char="(" charoff="50"><bold>HR (95% CI)</bold></th><th align="center" valign="top" charoff="50"><italic><bold>P</bold></italic><bold>-value</bold></th><th align="char" valign="top" char="(" charoff="50"><bold>HR (95% CI)</bold></th><th align="center" valign="top" charoff="50"><italic><bold>P</bold></italic><bold>-value</bold></th></tr></thead><tbody valign="top"><tr><td colspan="5" align="left" valign="top" charoff="50"><bold>Overall survival</bold><hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">⩽5% WL</td><td align="char" valign="top" char="(" charoff="50">1.6 (1.3–2.0)</td><td align="center" valign="top" charoff="50"><bold>&lt;0.001</bold></td><td align="char" valign="top" char="(" charoff="50">1.1 (0.9–1.4)</td><td align="center" valign="top" charoff="50">0.388</td></tr><tr><td align="left" valign="top" charoff="50">&gt;5–10% WL</td><td align="char" valign="top" char="(" charoff="50">2.3 (1.7–3.0)</td><td align="center" valign="top" charoff="50"><bold>&lt;0.001</bold></td><td align="char" valign="top" char="(" charoff="50">1.4 (1.2–1.9)</td><td align="center" valign="top" charoff="50"><bold>0.026</bold></td></tr><tr><td align="left" valign="top" charoff="50">&gt;10% WL<hr></hr></td><td align="char" valign="top" char="(" charoff="50">3.1 (2.2–4.3)<hr></hr></td><td align="center" valign="top" charoff="50"><bold>&lt;0.001</bold><hr></hr></td><td align="char" valign="top" char="(" charoff="50">1.7 (1.2–2.5)<hr></hr></td><td align="center" valign="top" charoff="50"><bold>0.002</bold><hr></hr></td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"><bold>Disease-specific survival</bold><hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">⩽5% WL</td><td align="char" valign="top" char="(" charoff="50">1.1 (0.8–1.7)</td><td align="center" valign="top" charoff="50">0.570</td><td align="char" valign="top" char="(" charoff="50">0.9 (0.6–1.4)</td><td align="center" valign="top" charoff="50">0.647</td></tr><tr><td align="left" valign="top" charoff="50">&gt;5–10% WL</td><td align="char" valign="top" char="(" charoff="50">1.7 (1.1–2.7)</td><td align="center" valign="top" charoff="50"><bold>0.021</bold></td><td align="char" valign="top" char="(" charoff="50">1.3 (0.8–2.1)</td><td align="center" valign="top" charoff="50">0.333</td></tr><tr><td align="left" valign="top" charoff="50">&gt;10% WL</td><td align="char" valign="top" char="(" charoff="50">3.3 (2.1–5.3)</td><td align="center" valign="top" charoff="50"><bold>&lt;0.001</bold></td><td align="char" valign="top" char="(" charoff="50">2.1 (1.2–3.5)</td><td align="center" valign="top" charoff="50"><bold>0.007</bold></td></tr></tbody></table><table-wrap-foot><fn id="t2-fn1"><p>Abbreviations: CI=confidence interval; HR=hazard ratio; WL=weight loss; TNM=tumour, node, metastasis; WHO=world health organisation.</p></fn><fn id="t2-fn2"><p><italic>P</italic>-values &lt;0.05 are shown in bold.</p></fn><fn id="t2-fn3"><label>a</label><p>Adjusted for age, gender, tumour location, TNM stage, prior head and neck surgery, and WHO performance score.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl3"><label>Table 3</label><caption><title>Cox regression analyses of the association between critical weight loss during radiotherapy and 5-year overall and disease-specific survival</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"></col><col align="left"></col><col align="left"></col><col align="left"></col><col align="left"></col></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"> </th><th colspan="2" align="center" valign="top" charoff="50"><bold>Crude model</bold></th><th colspan="2" align="center" valign="top" charoff="50"><bold>Adjusted model</bold><xref ref-type="fn" rid="t3-fn3">a</xref></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50"> <hr></hr></td><td align="left" valign="top" charoff="50"><bold>HR (95% CI)</bold><hr></hr></td><td align="left" valign="top" charoff="50"><italic><bold>P</bold></italic><bold>-value</bold><hr></hr></td><td align="left" valign="top" charoff="50"><bold>HR (95% CI)</bold><hr></hr></td><td align="left" valign="top" charoff="50"><italic><bold>P</bold></italic><bold>-value</bold><hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">Overall survival<xref ref-type="fn" rid="t3-fn4">b</xref></td><td align="char" valign="top" char="(" charoff="50">1.3 (1.1–1.6)</td><td align="char" valign="top" char="." charoff="50"><bold>0.010</bold></td><td align="char" valign="top" char="(" charoff="50">1.1 (0.9–1.4)</td><td align="char" valign="top" char="." charoff="50">0.295</td></tr><tr><td align="left" valign="top" charoff="50">Disease-specific survival<xref ref-type="fn" rid="t3-fn4">b</xref></td><td align="char" valign="top" char="(" charoff="50">1.7 (1.2–2.3)</td><td align="char" valign="top" char="." charoff="50"><bold>0.001</bold></td><td align="char" valign="top" char="(" charoff="50">1.7 (1.2–2.4)</td><td align="char" valign="top" char="." charoff="50"><bold>0.004</bold></td></tr></tbody></table><table-wrap-foot><fn id="t3-fn1"><p>Abbreviations: CI=confidence interval; HR=hazard ratio; TNM, tumour, node, metastasis; WHO=world health organisation.</p></fn><fn id="t3-fn2"><p><italic>P</italic>-values &lt;0.05 are shown in bold.</p></fn><fn id="t3-fn3"><label>a</label><p>Adjusted for age, gender, tumour location, TNM stage, WHO performance score, weight loss before radiotherapy, radiotherapy on the neck nodes and treatment modality.</p></fn><fn id="t3-fn4"><label>b</label><p>No critical weight loss <italic>vs</italic> critical weight loss (&gt;5% weight loss from the start of radiotherapy until week 8 and/or &gt;7.5% until week 12).</p></fn></table-wrap-foot></table-wrap></floats-group></article>